Subgroup | Number of study | Effects model | Pooled ES | Heterogeneity | ||
---|---|---|---|---|---|---|
HR [95% CI] | P | I2 | P-Value | |||
Type of therapy | ||||||
 ICIs | 4 | Fixed | 0.52[0.35,0.77] |  < 0.001 | 50.3% | 0.110 |
 Non-ICIs | 5 | Random | 2.31[0.89,5.97] | 0.086 | 68.5% | 0.013 |
Breast cancer subtype | ||||||
 HER2 +  | 4 | Random | 3.26[0.64,16.71] | 0.156 | 74.2% | 0.009 |
 TNBC | 4 | Fixed | 0.52[0.35,0.77] | 0.001 | 50.3% | 0.110 |
Sample source | ||||||
 tumor | 5 | Fixed | 0.53[0.38,0.74] |  < 0.001 | 35.4% | 0.185 |
 blood | 4 | Fixed | 3.37[1.34,8.44] | 0.01 | 38.1% | 0.183 |
TMB detection method | ||||||
 NGS | 8 | Random | 1.04[0.54,2.01] | 0.909 | 83.4% |  < 0.001 |
 WES | 1 | - | 0.63[0.28,1.14] | - | - | - |
TMB cutoff value | ||||||
  ≤ 5 Mut/Mb | 4 | Fixed | 3.37[1.34,8.44] | 0.01 | 38.1% | 0.183 |
  > 5 Mut/Mb | 4 | Fixed | 0.52[0.35,0.77] | 0.001 | 50.3% | 0.110 |